Skip to content
value.today
AYTU Bioscience, Inc. logo

AYTU Bioscience, Inc.

🇺🇸 Englewood, Colorado, USAPharmaceuticalsFounded 2015

AYTU Bioscience, Inc. is listed today as Aytu Bioscience: market value, financials and filings are on its company page.

Funding rounds

0 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.

Funding rounds of AYTU Bioscience, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2019$10 MPrivate placement after listing$10 to $50 million

AYTU Bioscience, Inc.: Private sale, Oct 2019

Investors in this round

2 investors had bought by the notice of Oct 31, 2019: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for AYTU Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, other: Series F Convertible Preferred Stock and Common Stock Purchase Warrants
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$800,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Green · Executive Officer
  • Jarrett Disbrow · Executive Officer
  • Josh Disbrow · Director, Executive Officer
  • Carl Dockery · Director
  • Gary Cantrell · Director
  • John Donofrio Jr. · Director
  • Ketan Mehta · Director
  • Michael Macaluso · Director
  • Steven Boyd · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ladenburg Thalmann & Co. Inc. (CRD 505) · Naples, FloridaSold in NY

Signed by David A. Green, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 31, 2019. Read the notice at the SEC.

equity, optionsSEC
Aug 2017$12 MPrivate placement after listing$10 to $50 million

AYTU Bioscience, Inc.: Private sale, Aug 2017

Investors in this round

70 investors had bought by the notice of Aug 24, 2017: 70 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for AYTU Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$12 M of $12 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,065,600
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory A. Gould · Executive Officer
  • Jarrett T. Disbrow · Executive Officer
  • Joshua R. Disbrow · Executive Officer, Director
  • Carl C. Dockery · Director
  • Gary V. Cantrell · Director
  • John A. Donofrio, Jr. · Director
  • Michael A. Macaluso · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Joseph Gunnar & Co., LLC (CRD 24795) · broker-dealer Joseph Gunnar & Co., LLC (CRD 24795) · New York,, New YorkSold in all US states
  • Fordham Financial Management, Inc. (CRD 20996) · broker-dealer Fordham Financial Management, Inc. (CRD 20996) · New York, New YorkSold in all US states

Remarks in the notice

  • On fees: “In addition to the cash commission above, Issuer also issued warrants to purchase a number of shares of the Issuer's Common Stock equal to 10% of the aggregate amount of the offering.”
  • On the use of proceeds: “Other than the payment of salaries and other customary compensation and benefits, no officer, director, or promoter will receive any payments from the proceeds of this offering.”

Signed by Gregory A. Gould, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 24, 2017. Read the notice at the SEC.

equity, optionsSEC
May 2017$2 MPrivate placement after listingUnder $2 million

AYTU Bioscience, Inc.: Private sale, May 2017

Investors in this round

16 investors had bought by the notice of May 16, 2017: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 1 investor is named for AYTU Bioscience, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M (amount offered: indefinite)
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory A. Gould · Executive Officer
  • Jarrett T. Disbrow · Executive Officer
  • Joshua R. Disbrow · Executive Officer, Director
  • Carl C. Dockery · Director
  • Gary V. Cantrell · Director
  • John A. Donofrio, Jr. · Director
  • Michael A. Macaluso · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The total offering amount may be up to a maximum of $6,925,000 in earnout payments and up to a maximum of $24,000,000 in milestone payments under the Merger Agreement.”
  • On the use of proceeds: “Other than the payment of salaries and other compensation and benefits, no officer, director or promoter will receive any payments from the proceeds of this offering.”
  • On a merger: “Pursuant to a Merger Agreement, the Issuer issued 2,500,000 shares of common stock to certain stockholders of Nuelle, Inc., a Delaware corporation, pursuant to the terms and conditions of the merger.”

Signed by Joshua Disbrow, Chief Executive Officer. Source: SEC Form D, newest notice filed May 16, 2017. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • As the listed company Aytu Bioscience, its revenue in fiscal 2026 came from these product and service lines: ADHD Portfolio $45.82 million (80%), E X X U A Portfolio $6.57 million (11%), The Pediatric Portfolio $5.14 million (9%), Product and Service, Other $40,000 (0%).

    Annual report (SEC XBRL) · Jun 2026

  • AYTU Bioscience, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2019).

    SEC Form D · Oct 2019

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Oct 2019

Products and services#

No products or services of AYTU Bioscience, Inc. are on record.

Investors#

1 named in official filings. Open an investor to see everything it has backed.

Investors in AYTU Bioscience, Inc.
InvestorKindAmountRoundRoleSource
Cerecor Inc.Companynot statednot statedHeld preferred stock, 10% owner (Form 3, 2020)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete.

Largest shareholders today

Institutions holding Aytu Bioscience shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by AYTU Bioscience, Inc.
NameRoleNamed in
David GreenExecutive officerOct 2019
Jarrett DisbrowExecutive officerOct 2019
Josh DisbrowExecutive officerOct 2019
Gregory A. GouldExecutive officerAug 2017
Jarrett T. DisbrowExecutive officerAug 2017
Joshua R. DisbrowExecutive officerAug 2017
Carl DockeryDirectorOct 2019
Gary CantrellDirectorOct 2019
John Donofrio Jr.DirectorOct 2019
Josh DisbrowDirectorOct 2019
Ketan MehtaDirectorOct 2019
Michael MacalusoDirectorOct 2019
Steven BoydDirectorOct 2019
Carl C. DockeryDirectorAug 2017
Gary V. CantrellDirectorAug 2017
John A. Donofrio, Jr.DirectorAug 2017
Joshua R. DisbrowDirectorAug 2017
Michael A. MacalusoDirectorAug 2017

Went public since 2013. Its SEC number is that of a company listed on a stock exchange.